Sanofi MS drug rejected in US gets an endorsement in Europe
Summary
Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory ...
Description
Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory ...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source